Is the heyday of domestic flu vaccines coming to an end?

By Moon, sung-ho | translator Lee,InBok

24.09.10 05:42:14

가나다라 0

Competition intensifies in the non-reimbursed vaccines for the elderly... price expected to be set in the KRW 40,000 range

Interest in use of the non-reimbursed COVID-19 treatment also rises…”Expectations on their use are low due to high dose price”

Competition among pharmaceutical and biotech companies with influenza (flu) vaccines is intensifying more than ever.

As more and more companies, including global pharmaceutical companies, are seeking to supply vaccines on-site, and specialized vaccines are being launched for each age group, the competition is expected to be unprecedented this autumn.

# In particular, the formation of a non-reimbursed market for both vaccines has become a hot topic in the field, especially in the context of the resurgence of COVID-19.

However, industry insiders do not expect large-scale co-vaccination to be carried out among adults, except for high-risk patients who are eligible for the Na

Moon, sung-ho(lib6983@dailypharm.com)

If you want to see the full article, please JOIN US (click)